Introduction
Thrombin is a proteolytic enzyme that cleaves fibrinopeptides A and B from the a-and f3-chains of fibrinogen. The resulting soluble fibrin monomers then polymerise to form the main physiological inhibitor of thrombin is antithrombin III (ATIII). 3 The physiological importance of ATIII is emphasised by the fact that it inhibits other activated coagulation factors, including factors IXa, Xa, XIa, and XIIa.-7 These inhibitory actions of ATIII are accelerated in the. presence of low heparin concentrations and ATIII is probably identical with the agent formerly known as plasma heparin cofactor. [8] [9] [10] A predisposition to venous thrombosis, such as is acquired during oestrogen treatment and surgery, has been associated with reduced ATIII concentrations.8 11-13 A clearer. association of venous thrombosis with reduced concentrations of this coagulation inhibitor occurs in the rare hereditary deficiency of ATIII.14 We describe here a large family in which major thromboembolic disease was associated with ATIII deficiency. To our knowledge. this represents the first such family studied in the British Isles. 
Patients and methods

Discussion
Several kindred affected by ATIII deficiency have been described in varying detail.'4 16-28 The family described here, which is to our knowledge the first family with ATIII deficiency identified in the United Kingdom, showed the characteristic association of reduced ATIII concentrations and major episodes of venous thrombosis. As in the families mentioned above, the ATIII deficiency in our family was found on both functional and immnunological assays and therefore probably represented a true reduction in ATIII protein synthesis. In the family described by Sas et al (1974)29 a variant form of ATIII was apparently produced, which was immunologically detectable but functionally abnormal. Although thrombotic events in our family were principally venous, as in the other series, one young man (III 4) had been found at necropsy to have a severe degree of arterial atheroma.
Other workers have described a rise in ATIII concentrations in patients with the deficiency during treatment with coumarin anticoagulant drugs." 20 22 Summary and conclusions Thirty-two first renal transplantations with cadaveric allografts were reviewed to see how many ofthe recipients had received blood transfusions preoperatively.
There was a significant difference in transplant survival between patients who had and patients who had not received blood transfusion before transplantation; this difference was entirely due to acute rejection within three months after transplantation in patients who had not received transfusion. Other factors studied had no effect on survival.
Introduction
Several recent papers have suggested that a blood transfusion given to patients before first renal transplantation with a cadaveric allograft increases the life of the transplant.1 2 We have therefore reviewed the 32 successive operations of this type carried out at this centre during February 1974 to January 1977 to see whether the recipients had been given a blood transfusion at any time preoperatively. By analysing a small, single-centre series we could examine more easily than in a larger series3 other factors that might have influenced graft survival and been associated with the receipt of blood. These other factors are often not considered in larger series.
Patients and methods
The 32 operations were carried out on 21 men and 11 women and were first transplantations with cadaver kidneys. Immunosuppression was effected with prednisolone and azathioprine in the standard manner. Sixteen of the patients were included in the MRC multicentre trial of antilymphocytic globulin (ALG) (Wellcome), eight being given ALG for the first 10 days after transplantation. Rejection episodes were treated with 1-6 g of methylprednisolone in 1-g doses
